Table 4.

ORs (95% CI)^* for TP53 polymorphisms in CIN3+/persistent HPV cases^† compared to random controls, stratified by HPV type (oncogenic HPV, HPV16, HPV18, and non-oncogenic HPV) and adjusted for age.

		HPV type
TP53 Polymorphism	Oncogenic‡ (599 cases/74 controls)	HPV16 (96 cases/21 controls)	HPV18 (27 cases/8 controls)	Non-oncogenic§ (268 cases/95 controls)
rs12951053
TT	1.0	1.0	1.0	1.0
GT	2.1 (1.1–4.1)	0.86 (0.26–2.8)	1.6 (0.26–9.7)	1.4 (0.79–2.5)
GG	NA	NA	NA	1.5 (0.32'7.5)
p-trend	0.01	0.95	0.48	0.23
rs1042522 (Pro72Arg)
GG	1.0	1.0	1.0	1.0
CG	1.8 (1.1–3.1)	1.2 (0.41–3.3)	6.7 (0.62–72.9)	1.5 (0.92–2.6)
CC	3.1 (1.1–9.0)	1.5 (0.16–14.3)	1.4 (0.11–17.3)	2.1 (0.85–4.9)
p-trend	0.01	0.68	0.33	0.04
rs1642785
GG	1.0	1.0	1.0	1.0
CG	1.3 (0.78–2.2)	0.33 (0.1–1.1)	3.7 (0.60–23.2)	1.4 (0.85–2.3)
CC	4.6 (1.1–19.7)	0.68 (0.1–7.0)	NA	2.0 (0.77–5.1)
p-trend	0.03	0.17	0.09	0.08

^*OR, odds ratio. CI, confidence interval. Adjusted for age.

^†All CIN3+ cases were included, regardless of HPV testing.

^‡Oncogenic HPV types included HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. HPV testing results were available for 65% of cases.

^§Non-oncogenic HPV types included HPV types 6, 11, 32, 40, 53, 54, 55, 61, 62, 67, 70, 71, 72, AE10 (74 variant), 81, 83, 84, 85, 89.